Key result
Quinizarin derivatives demonstrated promising anti-polymerase viral inhibitory activity against both HCV NS5B RNA polymerase and HIV-1 reverse transcriptase associated ribonuclease H activities.
Quinizarin derivatives show promise as dual inhibitors of HCV and HIV-1 polymerases in preclinical models.
Answers are grounded in this paper and cite their sources.
Preclinical quinizarin data warrant further antiviral development; leaves open any role in human HCV or HIV therapy.
Human immunodeficiency virus 1 (HIV-1) and Hepatitis C virus (HCV) affect 60 and 170 million infected individuals worldwide, respectively, and co-infection by both pathogens is often observed. This represents a serious public health problem that requires the identification of new drugs targeting essential phases of the life cycle of these two viruses. In this report, the synthesis and inhibitory activity of quinizarin derivatives towards both HCV NS5B polymerase and HIV-1 reverse transcriptase associated functions are reported. Our results demonstrate that anthraquinone derivatives are promising anti-polymerase viral inhibitors.
No takes yet. Share an insight, caveat, or question.
Tramontano et al. (2011) studied HIV-1 and HCV co-infection. Quinizarin derivatives was evaluated on Inhibitory activity towards HCV NS5B polymerase and HIV-1 reverse transcriptase associated functions. Quinizarin derivatives demonstrated promising anti-polymerase viral inhibitory activity against both HCV NS5B RNA polymerase and HIV-1 reverse transcriptase associated ribonuclease H activities.
Synapse has enriched 10 related papers. Consider them for comparative context: